Cytogenetic abnormalities in myelodysplastic syndrome: an overview

References

• Greenberg PL. The smoldering myeloid leukemic states. Clinical and biologic features. Blood 1983;61:1035–44.
   PubMed Web of Science ®Google Scholar
• Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation and environmental exposure. Semin Oncol 1992;19:47–84.
   PubMed Web of Science ®Google Scholar
• Ohyashiki JH, Ohyashiki K, Aizawa S, Kawakubo K, Shimamoto T, Iwama H, et al.. Replication errors in hematological neoplasias: genomic instability in progression of disease is different among different types of leukemia. Clin Cancer Res 1996;2:1583–9.
   PubMed Web of Science ®Google Scholar
• Sieber OM, Heinimann K, Tomlinson IP. Genomic instability—the engine of tumorigenesis? Nat Rev Cancer 2003;3:701–8.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 2003;27:95–120.
   PubMed Web of Science ®Google Scholar
• Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999;340:1649–60.
   PubMed Web of Science ®Google Scholar
• Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al.. Proposals for the classification of the myelodysplastic syndromes.Br J Haematol 1982;51:189–99.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–302.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al.. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835–49.
   PubMed Web of Science ®Google Scholar
• Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000;24:983–92.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al.. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–88
   PubMed Web of Science ®Google Scholar
• Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994;87:743–5.
   PubMed Web of Science ®Google Scholar
• Aul C, Gatterman N, Schneider W. Age-related incidence and other Epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992;82:358–67.
   PubMed Web of Science ®Google Scholar
• Anonymous French registry of acute leukemia and myelodysplastic syndromes. Age distribution and hemogram analysis of the 4496 cases recorded during 1982–1983 and classified according to FAB criteria. Groupe Francais de Morphologie Hematologique. Cancer 1987;60:1385–94.
   PubMedGoogle Scholar
• Michels SD, Mckenna RW, Arthur DC, Brunning RD. Therapy related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 1985;65:1364–72.
   PubMed Web of Science ®Google Scholar
• Mauritzson N, Albin M, Rylander L, Billström R, Ahlgren T, Mikoczy Z, et al.. Pooled analysis of clinical and cytogenetic features in treatment related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001. Leukemia 2002;16:2366–78.
   PubMed Web of Science ®Google Scholar
• Third MIC Cooperative Study Group. Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary myelodysplastic syndromes and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23–25, 1987. Cancer Genet Cytogenet 1988;32:1.
   PubMed Web of Science ®Google Scholar
• Boultwood J, Fidler C, Strickson AJ, Watkins F, Kostrzewa M, Jaju RJ, et al.. Transcription mapping of the 5q- syndrome critical region: cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs. Genomics 2000;66:26–34.
   PubMed Web of Science ®Google Scholar
• van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct hematological disorder with the deletion of long arm of no 5. chromosome. Nature 1974;251:437–8.
   PubMed Web of Science ®Google Scholar
• van den Berghe H, Michaux L. 5q-, twenty-five years later: a synopsis. Cancer Genet Cytogenet 1997;94:1–7.
   PubMed Web of Science ®Google Scholar
• Boultwood J, Fidler C, Lewis S, Kelly S, Sheridan H, Littlewood TJ, et al.. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: delineation of the critical region on 5q and identification of a 5q- breakpoint. Genomics 1994;19:425–32.
   PubMed Web of Science ®Google Scholar
• Pedersen B, Jensen IM. Clinical and prognostic implications of chromosome 5q deletions: 96 high resolution studied patients. Leukemia 1991;5:566–73.
   PubMed Web of Science ®Google Scholar
• Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L, et al.. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 2002,99:4638–41.
   PubMed Web of Science ®Google Scholar
• Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, et al.. Identification of RPS14 as the 5q- syndrome gene by RNA interference screen. Nature 2008;451:335–40.
   PubMed Web of Science ®Google Scholar
• Nagarajan L. Molecular anatomy of the 5q- chromosome. Leuk Lymphoma 1995;17:361–6.
   PubMed Web of Science ®Google Scholar
• Olney HJ, LeBeau MM. The myelodysplastic syndromes. Pathobiology and clinical management. In: , Bennett J M, ed, editor. The cytogenetics and molecular biology of myelodysplastic syndromes. New York: Marcel Dekker; 2002. p. 89–119.
   Google Scholar
• Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Della Porta MG, Killick S, et al.. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 2006;108:337–45.
   PubMed Web of Science ®Google Scholar
• Mathew P, Tefferi A, Dewald GW, Goldberg SL, Su J, Hoagland HC, et al.. The 5q- syndrome: a single-institutional study of 43 consecutive patients. Blood 1993;81:1040–5.
   PubMed Web of Science ®Google Scholar
• Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, et al.. Guidelines for the diagnosis and therapy of adult myelodysplastic syndrome. Br J Haematol 2003;120:187–200.
   PubMed Web of Science ®Google Scholar
• Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schegelberger B, Schoch C, et al.. Clinical: morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004;18:113–9.
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:67–71.
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl M, et al.. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998;92:68–75.
   PubMed Web of Science ®Google Scholar
• List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, et al.. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549–57.
   PubMed Web of Science ®Google Scholar
• West RR, Stafford DA, White AD, Bowen DT, Padua RA. Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. Blood 2000;95:2093–7.
   PubMed Web of Science ®Google Scholar
• Abdelrazik HN, Farawila HM, Sherif MA, AlAnsary M. Molecular characterization of chromosome 7 in AML and MDS patients. Afr J Health Sci 2006;13:33–42.
   PubMedGoogle Scholar
• Chen Z, Pasquini M, Hong B, Heikens M, Tsai S. The human Penumbra gene is mapped to a region on chromosome 7 frequently deleted in myeloid malignancies. Cancer Genet Cytogenet 2005;162:95–98.
   PubMed Web of Science ®Google Scholar
• Liang H, Fairman J, Claxton DF, Nowell PC, Green ED, Nagarajan L. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. Proc Natl Acad Sci USA 1998;95:3781–5.
   PubMed Web of Science ®Google Scholar
• Le Beau MM, Espinosa R, Davis EM, Eisenbart JD, Larson RA, Green ED. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996;88:1930–5.
   PubMed Web of Science ®Google Scholar
• Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al.. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110:4385–95.
   PubMed Web of Science ®Google Scholar
• Detlef haase: Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008;87:515–26.
   PubMed Web of Science ®Google Scholar
• Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003;17:1813–9.
   PubMed Web of Science ®Google Scholar
• Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 2004;104:1474–81.
   PubMed Web of Science ®Google Scholar
• Raj K, John A, Ho A, Chronis C, Khan S, Samuel J, et al.. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007;21:1937–44.
   PubMed Web of Science ®Google Scholar
• Gmidène A, Sennana H, Fenaux P, Laatiri A, Zarrouk M, Bouaziz H, et al.. Cytogenetic abnormalities in Tunisian de novo myelodysplastic syndrome: a comparison with other populations. Leuk Res 2008;32:1824–9.
   PubMed Web of Science ®Google Scholar
• Borgonovo T, Ribeiro EMSF, Cornelio DA, Schmid-Braz AT, Jamur VR, Wuicik L, et al.. Cytogenetic study of Brazilian patients with myelodysplastic syndrome (MDS). Genet Mol Biol 2005;28:654–60.
   Web of Science ®Google Scholar
• de Souza Fernandez T, Silva MLM, de Souza JM, Tabak D, Abdelhay E. Cytogenetic study of 50 Brazilian patients with primary myelodysplastic syndrome. Braz J Genet 1997;20:87–91.
   Google Scholar
• Solé F, Luno E, Sanzo C, Espinet B, Sanz GF, Cervera J, et al.. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005;90:1168–1178.
   PubMed Web of Science ®Google Scholar
• Pozdnyakova O, Miron PM, Tang G, Walter O, Raza A, Woda B, et al.. Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes. Cancer 2008;113:3331–40.
   PubMed Web of Science ®Google Scholar
• Li L, Liu XP, Nie L, Yu MH, Zhang Y, Qin TJ, et al.. Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients. Leuk Res 2009;33:1194–8.
   PubMed Web of Science ®Google Scholar
• Panani A. Cytogenetic findings in adult Greek myelodysplastic syndrome patients: predominance of single trisomy 8. In Vivo 2006;20:115–8.
   PubMed Web of Science ®Google Scholar
• Geddes AD, Bowen DT, Jacobs A. Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome. Br J Haematol 1990;76:194–202.
   PubMed Web of Science ®Google Scholar
• Wang XQ, Ryder J, Gross SA, Lin G, Irons RD. Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD. Int J Hematol 2009;890:361–9.
   Google Scholar
• Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al.. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110:4385–95.
   PubMed Web of Science ®Google Scholar
• Dakshinamurthy AG, Novitzky N, Bharadwaj R, Prakhya BM. Cytogenetic analysis of 52 Indian patients with de novo myelodysplastic syndromes — a comparative analysis of results with reports from Asia. Ann Hematol 2005;84:298–303.
   PubMed Web of Science ®Google Scholar
• Vundinti BR, Kerketta L, Jijina F, Ghosh K. Cytogenetic study of myelodysplasic syndrome from India. Indian J Med Res 2009;130:155–9.
   PubMed Web of Science ®Google Scholar
• Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, et al.. Clinical–cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43–52:.
   PubMed Web of Science ®Google Scholar
• Au WY, Ma SK, Wan TS, Man C, Kwong YL. Pentasomy 8q in therapy-related myelodysplastic syndrome due to cyclophosphamide therapy for fibrosing alveolitis. Cancer Genet Cytogenet 2003;141:79–82.
   PubMed Web of Science ®Google Scholar
• Yang W, Stotler B, Sevilla DW, Emmons FN, Murty VV, Alobeid B, et al.. FISH analysis in addition to G-band karyotyping: utility in evaluation of myelodysplastic syndromes? Leuk Res 2010;34:420–5.
   PubMed Web of Science ®Google Scholar
• Cuneo A, Bigoni R, Cavazzini F, Bardi A, Roberti MG, Agostini P, et al.. Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype. Leukemia 2002;16:1745–51.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi T, et al.. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503–3510.
   PubMed Web of Science ®Google Scholar
• Knapp RH, Dewald GW, Pierre RV. Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 1985;60:507–16.
   PubMed Web of Science ®Google Scholar
• Wattel E, Lai JL, Hebbar M, Preudhomme C. De novo myelodysplastic syndrome with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features? Leuk Res 1993;17:921–6.
   PubMed Web of Science ®Google Scholar
• Campbell LJ, Garson OM. The prognostic significance of deletion of the long Arm of chromosome 20 in myeloid disorders. Leukemia 1994;8:67.
   PubMed Web of Science ®Google Scholar
• United Kingdom Cytogenetics Group (UKCCG). Loss of the Y chromosome from normal and neoplastic bone marrows. Genes Chromosomes Cancer 1992;5:83.
   PubMed Web of Science ®Google Scholar
• Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al.. New and comprehensive cytogenetic prognostication and categorization in MDS. Blood 2006;108:252.
   Web of Science ®Google Scholar
• Morel P, Hebbar M, Lai JL, Duhamel A. Cytogenetic analysis has strong Prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993;7:1315.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al.. The importance of diagnostic cytogenetics on outcome AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998;92:2322–33.
   PubMed Web of Science ®Google Scholar
• Toyama K, Ohyashiki K, Yoshida Y, Abe T. Clinical implications of chromosomal abnormalities in 401 patients with MDS: a multicentric study in Japan. Leukemia 1993;7:499.
   PubMed Web of Science ®Google Scholar
• Wattel E, Laï JL, Hebbar M, Preudhomme C, Grahek D, Morel P, et al.. De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features? Leuk Res 1993;17:921.
   PubMed Web of Science ®Google Scholar